Thoracic medical oncologist, Perlmutter Cancer Center NYU Langone Health. Tweets are my own and not medical advice
New York, NY
Joined November 2010
- Tweets213
- Following864
- Followers2.1K
- Likes2.5K
Joshua Sabari, MD retweeted
Lung cancer updates from @JSabari of @nyulangone @Perlmutter_CC new data #ASCO26 @Aiims1742 @nyugrossman
Joshua Sabari, MD retweeted
From emerging therapies to new clinical research, #ASCO2026 brings oncology experts to Chicago, May 29–June 2. Join us for presentations from @nyulangone physicians and researchers.
Check out the full list of our presenters: bit.ly/4fdKFt2
Joshua Sabari, MD retweeted
Join Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, FCAHS, Pasi A. Jänne, MD, PhD, FASCO, and Joshua Sabari, MD (@JSabari), on 5/30 at 6:30 PM CDT during #ASCO26 for an #NSCLC #MedEd event. Produced with @LUNGevity ➡️ bit.ly/2026EGFRLung-T #Oncology
Joshua Sabari, MD retweeted
🚨@OncBrothers are moderating the 3rd Annual Upstate Cancer Symposium!
⭐️Full Day CME event bringing the latest in oncology to community practice!
@PTarantinoMD @jainprantesh @rukitamehta @rutikamehtaMD @DrR_DUNNE
#OncTwitter #MedTwitter
Full details: oncupdates.com/article/oncol…
Joshua Sabari, MD retweeted
First line oral targeted therapy for advanced non small cell lung cancer, including responses observed in dreaded brain metastatic disease (thanks to the chemistry behind Zongertinib crossing BBB). New study in @NEJM
nejm.org/doi/full/10.1056/NE…
@JSabari @Perlmutter_CC
Joshua Sabari, MD retweeted
Permitting NGS results do not identify oncogenic drivers or co-mutations that would favor alternative approaches (i.e., non IO, TKI instead).
Joshua Sabari, MD retweeted
Zongertinib (oral TKI) now @US_FDA approved based off #BeamionLung1 in previously treated metastatic NSCLC w/ HER2+:
- 71% ORR w/ 14.1mos mDoR
- mPFS 12.4%
- ≥Gr 3 AEs in less than 20%. Common AEs includied diarrhea and rash
#OncTwitter #MedTwitter
Missed out on AACR 2025? Check out the highlights from Beamion Lung-1! @sawyer_bawek highlights the 🔑 takeaways below!
oncupdates.com/articles/beam…
🔹ORR 71%
🔹mPFS 12.4 months
🔹Intracranial ORR 41%
🔹Improved AE profile
@OncBrothers @AACR #MedTwitter #FOAMed #LungCancer #NSCLC
Joshua Sabari, MD retweeted
FDA approves zongertinib 120mg po daily for previously treated advanced #HER2 NSCLC. In the phase 1b Beamion-LUNG 1 study @NEJM, RR 71% (42% post ADC), DOR 14.1m, intracranial RR 41%. Main toxicity is diarrhea (56%, 48% grade 1), no ILD.
fda.gov/drugs/resources-info…
Joshua Sabari, MD retweeted
Discussing data hot off the press here at #HawaiiLung25.
Dr. Joshua Sabari reviews the latest FDA approval of DatoDXd for our patients with EGFR+ mNSCLC.
Joshua Sabari, MD retweeted
Advancements Reshape Treatment for Non-Small Cell Lung Cancer @JSabari @Perlmutter_CC @jainprantesh @RoswellPark #LungCancer curetoday.com/view/advanceme…
Joshua Sabari, MD retweeted
📣 HCPs 📣
Do you treat pts w/ rare alterations of #NSCLC?
Medical Oncologist Dr @JSabari and Debra Montague (President of @LungCancerEu/founder of @UKALK1) share views on:
➡️The pt pathway
➡️#MedOnc vs Patient needs
➡️The support currently available
Watch the video/listen on Spotify/Apple: cor2ed.com/lung-connect/prog…
🤝Endorsed by several Patient Advocacy Groups, inc. @WarOnCancer @BrafBombers @Exon20Group @metcrusaders @BiomarkerCo @LungCancerEu & ALK Positive Europe
Supported by an Independent Educational Grant from Boehringer Ingelheim
#MedEd #NSCLC #PrecisionMedicine 📷
Joshua Sabari, MD retweeted
Join Joshua Sabari, MD (@JSabari), Jonathan W. Goldman, MD, Gilberto Lopes, MD, MBA, FASCO (@GlopesMd), Zosia Piotrowska, MD, MHS (@ZPiotrowskaMD) & @OncBrothers, on 5/31 at 6:30 PM CDT during #ASCO25 for an #NSCLC #MedEd event. Produced w/ @Lungevity.
bit.ly/25TT-T
Joshua Sabari, MD retweeted
Our goal is to help early career investigators foster collaborations early in their careers and support their important work. YOU are our future.
Please share with early investigators you know!
Submit your abstract for the #EGFRSummit Don’t miss the the 9/30 deadline! ce.ceconcepts.com/EGFR24
@ZPiotrowskaMD @christine_lovly @maryjofidlerMD @StephenVLiu @HelenaYu923 @EGFRResisters
Joshua Sabari, MD retweeted
🚨24 Hours to go until @JSabari and @mvnegrao delve into the latest NSCLC data presented in Chicago! Calling all thoracic oncologists, surgeons and pulmonologists to join the LIVE discussion and earn CME credits! ⏰ Set a reminder here: ms.spr.ly/6017YoO7W
Joshua Sabari, MD retweeted
PALOMA-3 results @JCO_ASCO after #ASCO24 oral presentation. Subcutaneous vs intravenous amivantamab (with lazertinib) in previously treated #EGFR NSCLC (n=418). Primary PK endpoint shows non-inferiority. Subcutaneous with much better safety profile.
ascopubs.org/doi/10.1200/JCO…
Joshua Sabari, MD retweeted
Lung Ca Highlights from #ASCO24 w/ @JSabari
- #LAURA
- #MARIPOSA+#PALOMA3
- #CROWN
- #ADRIATIC
Full 🗣️
- Oncbrothers.com/asco24-lung
- targetedonc.com/data-dialogu…
- The “Oncology Brothers” podcast
#lcsm @ASCO #OncTwitter #MedTwitter @TargetedOnc @jillfeldman4 @EGFRResisters
Joshua Sabari, MD retweeted
⏰ NEW DEADLINE ALERT ⏰
Hurry, it's your final shot! Submit your abstract for #EGFRSummit by 9/11.
SUBMIT HERE: ce.ceconcepts.com/EGFR23
@jillfeldman4 @ivybelkins @ZPiotrowskaMD @egfrresisters @StephenVLiu @HelenaYu923 @JSabari @maryjofidlerMD @christine_lovly #EGFR #LCSM
Joshua Sabari, MD retweeted
.@AlexSpiraMDPhD led a panel of experts to discuss current treatment options for patients with EGFR exon 20 non–small cell lung cancer. #NSCLC | @JSabari @MNagasaka @ChristineBestv1 @DasMillie11
ow.ly/6N8w50PBEzG
Joshua Sabari, MD retweeted
Our study of clinical/genomic predictors of response and toxicity to sotorasib in KRAS G12C+ NSCLC we recently presented at #ASCO23 is out today @JCOPO_ASCO.
Thanks to @RielyMD @KCArbourMD @bherzbergmd @JSabari for the mentorship and collaboration!
ascopubs.org/doi/abs/10.1200…
Joshua Sabari, MD retweeted
Treating patients with KRAS-mutant lung cancer and untreated CNS metastasis with Adagrasib shows promising intracranial activity response, according to a @JCO_ASCO trial update. #NSCLC
Read early results, co-authored by @JSabari: bit.ly/3qZ111D
